Cargando…
Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432/ https://www.ncbi.nlm.nih.gov/pubmed/33831052 http://dx.doi.org/10.1371/journal.pone.0249592 |
_version_ | 1783676163784179712 |
---|---|
author | Mohd, Rozita Mohammad Kazmin, Nur Ezzaty Abdul Cader, Rizna Abd Shukor, Nordashima Wong, Yin Ping Shah, Shamsul Azhar Alfian, Nurwardah |
author_facet | Mohd, Rozita Mohammad Kazmin, Nur Ezzaty Abdul Cader, Rizna Abd Shukor, Nordashima Wong, Yin Ping Shah, Shamsul Azhar Alfian, Nurwardah |
author_sort | Mohd, Rozita |
collection | PubMed |
description | INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and the factors affecting it. METHODS: This study included all biopsy-proven IgAN patients with ≥ 1year follow-up. Patients with diabetes mellitus at diagnosis and secondary IgAN were excluded. Medical records were reviewed for demographics, clinical presentation, blood pressure, 24-hour urine protein, serum creatinine, renal biopsy and treatment received. The primary outcome was defined as combined event of 50% estimated glomerular filtration rate (eGFR) reduction or ESRD. RESULTS: We included 130 (74 females; 56 males) patients of mean age 38.0 ± 14.0 years and median eGFR of 75.2 (interquartile range (IQR) 49.3–101.4) ml/min/1.73m(2). Eighty-four (64.6%) were hypertensive at presentation, 35 (26.9%) had nephrotic syndrome and 57 (43.8%) had nephrotic range proteinuria (NRP). Median follow-up duration was 7.5 (IQR 4.0–13.0) years. It was noted that 18 (13.8%) developed ESRD and 34 (26.2%) reached the primary outcome. Annual eGFR decline was -2.1 (IQR -5.3 to -0.1) ml/min/1.73m2/year, with median survival of 20 years. Survival rates from the combined event (50% decrease in eGFR or ESRD) at 10, 20 and 30 years were 80%, 53% and 25%, while survival from ESRD were 87%, 73% and 65%, respectively. In the univariate analysis, time-average proteinuria (hazard ratio (HR) = 2.41, 95% CI 1.77–3.30), eGFR <45ml/min/1.73m2 at biopsy (HR = 2.35, 95% CI 1.03–5.32), hypertension (HR = 2.81, 95% CI 1.16–6.80), mean arterial pressure (HR = 1.02, 95% CI 1.01–1.04), tubular atrophy/interstitial fibrosis score (HR = 3.77, 95% CI 1.84–7.73), and cellular/fibrocellular crescent score (HR = 2.44, 95% CI 1.19–5.00) were found to be significant. Whereas only time-average proteinuria (TA-proteinuria) remained as a significant predictor in the multivariate analysis (HR = 2.23, 95% CI 1.57–3.16). CONCLUSION: In our cohort, TA-proteinuria was the most important predictor in the progression of IgAN, irrespective of degree of proteinuria at presentation. |
format | Online Article Text |
id | pubmed-8031432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-80314322021-04-14 Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience Mohd, Rozita Mohammad Kazmin, Nur Ezzaty Abdul Cader, Rizna Abd Shukor, Nordashima Wong, Yin Ping Shah, Shamsul Azhar Alfian, Nurwardah PLoS One Research Article INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and the factors affecting it. METHODS: This study included all biopsy-proven IgAN patients with ≥ 1year follow-up. Patients with diabetes mellitus at diagnosis and secondary IgAN were excluded. Medical records were reviewed for demographics, clinical presentation, blood pressure, 24-hour urine protein, serum creatinine, renal biopsy and treatment received. The primary outcome was defined as combined event of 50% estimated glomerular filtration rate (eGFR) reduction or ESRD. RESULTS: We included 130 (74 females; 56 males) patients of mean age 38.0 ± 14.0 years and median eGFR of 75.2 (interquartile range (IQR) 49.3–101.4) ml/min/1.73m(2). Eighty-four (64.6%) were hypertensive at presentation, 35 (26.9%) had nephrotic syndrome and 57 (43.8%) had nephrotic range proteinuria (NRP). Median follow-up duration was 7.5 (IQR 4.0–13.0) years. It was noted that 18 (13.8%) developed ESRD and 34 (26.2%) reached the primary outcome. Annual eGFR decline was -2.1 (IQR -5.3 to -0.1) ml/min/1.73m2/year, with median survival of 20 years. Survival rates from the combined event (50% decrease in eGFR or ESRD) at 10, 20 and 30 years were 80%, 53% and 25%, while survival from ESRD were 87%, 73% and 65%, respectively. In the univariate analysis, time-average proteinuria (hazard ratio (HR) = 2.41, 95% CI 1.77–3.30), eGFR <45ml/min/1.73m2 at biopsy (HR = 2.35, 95% CI 1.03–5.32), hypertension (HR = 2.81, 95% CI 1.16–6.80), mean arterial pressure (HR = 1.02, 95% CI 1.01–1.04), tubular atrophy/interstitial fibrosis score (HR = 3.77, 95% CI 1.84–7.73), and cellular/fibrocellular crescent score (HR = 2.44, 95% CI 1.19–5.00) were found to be significant. Whereas only time-average proteinuria (TA-proteinuria) remained as a significant predictor in the multivariate analysis (HR = 2.23, 95% CI 1.57–3.16). CONCLUSION: In our cohort, TA-proteinuria was the most important predictor in the progression of IgAN, irrespective of degree of proteinuria at presentation. Public Library of Science 2021-04-08 /pmc/articles/PMC8031432/ /pubmed/33831052 http://dx.doi.org/10.1371/journal.pone.0249592 Text en © 2021 Mohd et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Mohd, Rozita Mohammad Kazmin, Nur Ezzaty Abdul Cader, Rizna Abd Shukor, Nordashima Wong, Yin Ping Shah, Shamsul Azhar Alfian, Nurwardah Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title | Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title_full | Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title_fullStr | Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title_full_unstemmed | Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title_short | Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience |
title_sort | long term outcome of immunoglobulin a (iga) nephropathy: a single center experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432/ https://www.ncbi.nlm.nih.gov/pubmed/33831052 http://dx.doi.org/10.1371/journal.pone.0249592 |
work_keys_str_mv | AT mohdrozita longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT mohammadkazminnurezzaty longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT abdulcaderrizna longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT abdshukornordashima longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT wongyinping longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT shahshamsulazhar longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience AT alfiannurwardah longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience |